AFMD - Affimed rises after data on blood cancer therapy from phase 1/2 study

The shares of Affimed (NASDAQ:AFMD) have added 13% in the pre-market Monday after the clinical-stage biotech announced a data update from an ongoing phase 1/2 study for its lead candidate in patients with certain blood cancer. The investigator-sponsored trial was designed to evaluate AFM13 precomplexed with cord blood-derived natural killer (cbNK) cells among 22 patients with CD30-positive relapsed or refractory Hodgkin and non-Hodgkin lymphomas who had received a median of seven prior lines of therapy. Out of 19 patients who were evaluable for response, 13 were treated at the recommended phase 2 dose (RP2D) of 108 NK/Kg, including 12 with Hodgkin Lymphoma and one with non-Hodgkin Lymphoma. As of the cut-off date, the study demonstrated 100% objective response rate (ORR), with a complete response (CR) rate of 62% at the RP2D among 8 patients, the company said. The treatment was found to be well tolerated with no incidences of cytokine release syndrome,

For further details see:

Affimed rises after data on blood cancer therapy from phase 1/2 study